Australia markets close in 5 hours 10 minutes

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
25.09-1.39 (-5.25%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close26.48
Open26.47
Bid25.12 x 800
Ask31.95 x 1200
Day's range24.92 - 26.72
52-week range14.27 - 36.42
Volume367,563
Avg. volume513,690
Market cap1.296B
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)-1.55
Earnings date28 Feb 2022 - 04 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est45.33
  • GlobeNewswire

    Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone

    BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon. The U.S. Food and Drug Administration (FDA) accepted Neurocrine’s protocol amendment that expands the study population to incl

  • GlobeNewswire

    Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022

    BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We are entering 2022 with an immense amount of positive momentum, building upon the strong efficacy data from our XEN1101 Phase 2b X-TOLE clinical trial announced in the fourth quarter of 2021. We have set clear business objectives f

  • Simply Wall St.

    We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...